HomeCompareSGTPY vs ABBV

SGTPY vs ABBV: Dividend Comparison 2026

SGTPY yields 1219.86% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SGTPY wins by $108814454.68M in total portfolio value
10 years
SGTPY
SGTPY
● Live price
1219.86%
Share price
$0.51
Annual div
$6.22
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$108814454.79M
Annual income
$93,703,778,182,393.78
Full SGTPY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SGTPY vs ABBV

📍 SGTPY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGTPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGTPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGTPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGTPY
Annual income on $10K today (after 15% tax)
$103,688.33/yr
After 10yr DRIP, annual income (after tax)
$79,648,211,455,034.72/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SGTPY beats the other by $79,648,211,433,978.72/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGTPY + ABBV for your $10,000?

SGTPY: 50%ABBV: 50%
100% ABBV50/50100% SGTPY
Portfolio after 10yr
$54407227.44M
Annual income
$46,851,889,103,582.77/yr
Blended yield
86.11%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SGTPY
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGTPY buys
0
ABBV buys
0
No recent congressional trades found for SGTPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGTPYABBV
Forward yield1219.86%3.06%
Annual dividend / share$6.22$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$108814454.79M$102.3K
Annual income after 10y$93,703,778,182,393.78$24,771.77
Total dividends collected$107689252.78M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SGTPY vs ABBV ($10,000, DRIP)

YearSGTPY PortfolioSGTPY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$132,686$121,986.27$11,550$430.00+$121.1KSGTPY
2$1,654,676$1,512,701.34$13,472$627.96+$1.64MSGTPY
3$19,400,664$17,630,161.43$15,906$926.08+$19.38MSGTPY
4$213,944,972$193,186,261.19$19,071$1,382.55+$213.93MSGTPY
5$2,219,951,753$1,991,030,632.80$23,302$2,095.81+$2219.93MSGTPY
6$21,683,273,923$19,307,925,547.58$29,150$3,237.93+$21683.24MSGTPY
7$199,452,739,630$176,251,636,532.04$37,536$5,121.41+$199452.70MSGTPY
8$1,728,595,482,164$1,515,181,050,760.40$50,079$8,338.38+$1728595.43MSGTPY
9$14,122,127,668,072$12,272,530,502,156.45$69,753$14,065.80+$14122127.60MSGTPY
10$108,814,454,787,231$93,703,778,182,393.78$102,337$24,771.77+$108814454.68MSGTPY

SGTPY vs ABBV: Complete Analysis 2026

SGTPYStock

SGTPY is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in SGTPY shares.

Full SGTPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SGTPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGTPY vs SCHDSGTPY vs JEPISGTPY vs OSGTPY vs KOSGTPY vs MAINSGTPY vs JNJSGTPY vs MRKSGTPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.